Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib.

Literature DB >> 27887955

Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib.

Brett King¹, Alfred Ian Lee², Jaehyuk Choi³.

Abstract

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2016 PMID： 27887955 PMCID： PMC5387413 DOI： 10.1016/j.jid.2016.10.044

Source DB: PubMed Journal: J Invest Dermatol ISSN： 0022-202X Impact factor: 8.551

× No keyword cloud information.

9 in total

1. Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome.

Authors: Sarah Walker; Chen Wang; Trent Walradt; Bok Sil Hong; Justin R Tanner; Jonathan L Levinsohn; Gerald Goh; Antonio Subtil; Stuart R Lessin; Warren R Heymann; Eric C Vonderheid; Brett A King; Richard P Lifton; Jaehyuk Choi
Journal: Blood Date: 2015-12-23 Impact factor: 22.113

2. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report.

Authors: Amy D Klion; Bruce S Bochner; Gerald J Gleich; Thomas B Nutman; Marc E Rothenberg; Hans-Uwe Simon; Michael E Wechsler; Peter F Weller
Journal: J Allergy Clin Immunol Date: 2006-05-03 Impact factor: 10.793

Review 3. How I treat hypereosinophilic syndromes.

Authors: Amy D Klion
Journal: Blood Date: 2015-05-11 Impact factor: 22.113

4. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes.

Authors: Peter Valent; Amy D Klion; Hans-Peter Horny; Florence Roufosse; Jason Gotlib; Peter F Weller; Andrzej Hellmann; Georgia Metzgeroth; Kristin M Leiferman; Michel Arock; Joseph H Butterfield; Wolfgang R Sperr; Karl Sotlar; Peter Vandenberghe; Torsten Haferlach; Hans-Uwe Simon; Andreas Reiter; Gerald J Gleich
Journal: J Allergy Clin Immunol Date: 2012-03-28 Impact factor: 10.793

5. The transcription factor STAT3 is required for T helper 2 cell development.

Authors: Gretta L Stritesky; Rajarajeswari Muthukrishnan; Sarita Sehra; Ritobrata Goswami; Duy Pham; Jared Travers; Evelyn T Nguyen; David E Levy; Mark H Kaplan
Journal: Immunity Date: 2011-01-06 Impact factor: 31.745

6. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia.

Authors: H U Simon; S G Plötz; R Dummer; K Blaser
Journal: N Engl J Med Date: 1999-10-07 Impact factor: 91.245

Review 7. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.

Authors: Jason Gotlib
Journal: Am J Hematol Date: 2014-03 Impact factor: 10.047

Review 8. Lymphocytic variant hypereosinophilic syndromes.

Authors: Florence Roufosse; Elie Cogan; Michel Goldman
Journal: Immunol Allergy Clin North Am Date: 2007-08 Impact factor: 3.479

9. JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells.

Authors: Clodagh Keohane; Shahram Kordasti; Thomas Seidl; Pilar Perez Abellan; Nicholas S B Thomas; Claire N Harrison; Donal P McLornan; Ghulam J Mufti
Journal: Br J Haematol Date: 2015-06-15 Impact factor: 6.998

9 in total

18 in total

Review 1. Hypereosinophilic syndrome: approach to treatment in the era of precision medicine.

Authors: Amy Klion
Journal: Hematology Am Soc Hematol Educ Program Date: 2018-11-30

Review 2. Consultation for Elevated Blood Eosinophils: Clinical Presentations, High Value Diagnostic Tests, and Treatment Options.

Authors: Paneez Khoury; Bruce S Bochner
Journal: J Allergy Clin Immunol Pract Date: 2018 Sep - Oct

Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib.

1. Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome.

2. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report.

Review 3. How I treat hypereosinophilic syndromes.

4. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes.

5. The transcription factor STAT3 is required for T helper 2 cell development.

6. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia.

Review 7. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.

Review 8. Lymphocytic variant hypereosinophilic syndromes.

9. JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells.

Review 1. Hypereosinophilic syndrome: approach to treatment in the era of precision medicine.

Review 2. Consultation for Elevated Blood Eosinophils: Clinical Presentations, High Value Diagnostic Tests, and Treatment Options.

Review 3. T-cell positioning by chemokines in autoimmune skin diseases.

Review 4. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

5. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

Review 6. Diagnosis and Novel Approaches to the Treatment of Hypereosinophilic Syndromes.

Review 7. JAK inhibitors in dermatology: The promise of a new drug class.

8. Case for diagnosis. Erythroderma as manifestation of hypereosinophilic syndrome.

Review 9. The eosinophil: For better or worse, in sickness and in health.

Review 10. Approach to Eosinophilia Presenting With Pulmonary Symptoms.